1. Streeck H, Nixon DF. T cell immunity in acute HIV-1 infection. J Infect Dis. 2010;202 Suppl 2:S302-8. DOI: 10.1086/655652.
2. Hu J, Gardner MB, Miller CJ. Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells. J Virol. 2000;74(13):6087-95. DOI: 10.1128/jvi.74.13.6087-6095.2000.
3. Moore JP, Kitchen SG, Pugach P, Zack JA. The CCR5 and CXCR4 coreceptors--central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses. 2004;20(1):111-26. DOI: 10.1089/088922204322749567.
4. Kahn JO, Walker BD. Acute human immunodeficiency virus type 1 infection. N Engl J Med. 1998;339(1):33-9. DOI: 10.1056/NEJM199807023390107.
5. Lackner AA, Lederman MM, Rodriguez B. HIV pathogenesis: the host. Cold Spring Harb Perspect Med. 2012;2(9):a007005. DOI: 10.1101/cshperspect.a007005.
6. Streeck H, Jolin JS, Qi Y, Yassine-Diab B, Johnson RC, Kwon DS, et al. Human immunodeficiency virus type 1-specific CD8+ T-cell responses during primary infection are major determinants of the viral set point and loss of CD4+ T cells. J Virol. 2009;83(15):7641-8. DOI: 10.1128/JVI.00182-09.
7. Mellors JW, Margolick JB, Phair JP, Rinaldo CR, Detels R, Jacobson LP, et al. Prognostic value of HIV-1 RNA, CD4 cell count, and CD4 Cell count slope for progression to AIDS and death in untreated HIV-1 infection. JAMA. 2007;297(21):2349-50. DOI: 10.1001/jama.297.21.2349.
8. Sewell AK, Price DA, Oxenius A, Kelleher AD, Phillips RE. Cytotoxic T lymphocyte responses to human immunodeficiency virus: control and escape. Stem Cells. 2000;18(4):230-44. DOI: 10.1634/stemcells.18-4-230.
9. Mattapallil JJ, Douek DC, Hill B, Nishimura Y, Martin M, Roederer M. Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature. 2005;434(7037):1093-7. DOI: 10.1038/nature03501.
10. Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, Kalams SA, et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science. 1997;278(5342):1447-50. DOI: 10.1126/science.278.5342.1447.
11. Lichterfeld M, Kaufmann DE, Yu XG, Mui SK, Addo MM, Johnston MN, et al. Loss of HIV-1-specific CD8+ T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4+ T cells. J Exp Med. 2004;200(6):701-12. DOI: 10.1084/jem.20041270.
12. Rosendahl Huber S, van Beek J, de Jonge J, Luytjes W, van Baarle D. T cell responses to viral infections - opportunities for Peptide vaccination. Front Immunol. 2014;5:171. DOI: 10.3389/fimmu.2014.00171.
13. Koelsch KK, Boesecke C, McBride K, Gelgor L, Fahey P, Natarajan V, et al. Impact of treatment with raltegravir during primary or chronic HIV infection on RNA decay characteristics and the HIV viral reservoir. AIDS. 2011;25(17):2069-78. DOI: 10.1097/QAD.0b013e32834b9658.
14. Braun DL, Kouyos RD, Balmer B, Grube C, Weber R, Gunthard HF. Frequency and Spectrum of Unexpected Clinical Manifestations of Primary HIV-1 Infection. Clin Infect Dis. 2015;61(6):1013-21. DOI: 10.1093/cid/civ398.
15. Lavreys L, Baeten JM, Chohan V, McClelland RS, Hassan WM, Richardson BA, et al. Higher set point plasma viral load and more-severe acute HIV type 1 (HIV-1) illness predict mortality among high-risk HIV-1-infected African women. Clin Infect Dis. 2006;42(9):1333-9. DOI: 10.1086/503258.
16. Kelley CF, Barbour JD, Hecht FM. The relation between symptoms, viral load, and viral load set point in primary HIV infection. J Acquir Immune Defic Syndr. 2007;45(4):445-8. DOI: 10.1097/QAI.0b013e318074ef6e.
17. Pedersen C, Lindhardt BO, Jensen BL, Lauritzen E, Gerstoft J, Dickmeiss E, et al. Clinical course of primary HIV infection: consequences for subsequent course of infection. BMJ. 1989;299(6692):154-7. DOI: 10.1136/bmj.299.6692.154.
18. Cooper DA, Gold J, Maclean P, Donovan B, Finlayson R, Barnes TG, et al. Acute AIDS retrovirus infection. Definition of a clinical illness associated with seroconversion. Lancet. 1985;1(8428):537-40. DOI: 10.1016/s0140-6736(85)91205-x.
19. Ridzon R, Gallagher K, Ciesielski C, Ginsberg MB, Robertson BJ, Luo CC, et al. Simultaneous transmission of human immunodeficiency virus and hepatitis C virus from a needle-stick injury. N Engl J Med. 1997;336(13):919-22. DOI: 10.1056/NEJM199703273361304.
20. Moss PJ, Read RC, Kudesia G, McKendrick MW. Prolonged cryptosporidiosis during primary HIV infection. J Infect. 1995;30(1):51-3. DOI: 10.1016/s0163-4453(95)92873-1.
21. Vento S, Di Perri G, Garofano T, Concia E, Bassetti D. Pneumocystis carinii pneumonia during primary HIV-1 infection. Lancet. 1993;342(8862):24-5. DOI: 10.1016/0140-6736(93)91884-o.
22. Hagberg L, Malmvall BE, Svennerholm L, Alestig K, Norkrans G. Guillain-Barre syndrome as an early manifestation of HIV central nervous system infection. Scand J Infect Dis. 1986;18(6):591-2. DOI: 10.3109/00365548609021668.
23. Denning DW, Anderson J, Rudge P, Smith H. Acute myelopathy associated with primary infection with human immunodeficiency virus. Br Med J (Clin Res Ed). 1987;294(6565):143-4. DOI: 10.1136/bmj.294.6565.143.
24. Schacker T, Collier AC, Hughes J, Shea T, Corey L. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med. 1996;125(4):257-64. DOI: 10.7326/0003-4819-125-4-199608150-00001.
25. Raffi F, Boudart D, Billaudel S. Acute co-infection with human immunodeficiency virus (HIV) and cytomegalovirus. Ann Intern Med. 1990;112(3):234-5. DOI: 10.7326/0003-4819-112-3-234.
26. Saag MS. HIV Infection - Screening, Diagnosis, and Treatment. N Engl J Med. 2021;384(22):2131-43. DOI: 10.1056/NEJMcp1915826.
27. Delaney KP, Hanson DL, Masciotra S, Ethridge SF, Wesolowski L, Owen SM. Time Until Emergence of HIV Test Reactivity Following Infection With HIV-1: Implications for Interpreting Test Results and Retesting After Exposure. Clin Infect Dis. 2017;64(1):53-9. DOI: 10.1093/cid/ciw666.
28. Busch MP, Satten GA. Time course of viremia and antibody seroconversion following human immunodeficiency virus exposure. Am J Med. 1997;102(5B):117-24; discussion 25-6. DOI: 10.1016/s0002-9343(97)00077-6.
29. Curlin ME, Gvetadze R, Leelawiwat W, Martin M, Rose C, Niska RW, et al. Analysis of False-Negative Human Immunodeficiency Virus Rapid Tests Performed on Oral Fluid in 3 International Clinical Research Studies. Clin Infect Dis. 2017;64(12):1663-9. DOI: 10.1093/cid/cix228.
30. Donnell D, Ramos E, Celum C, Baeten J, Dragavon J, Tappero J, et al. The effect of oral preexposure prophylaxis on the progression of HIV-1 seroconversion. AIDS. 2017;31(14):2007-16. DOI: 10.1097/QAD.0000000000001577.
31. Masciotra S, Luo W, Westheimer E, Cohen SE, Gay CL, Hall L, et al. Performance evaluation of the FDA-approved Determine HIV-1/2 Ag/Ab Combo assay using plasma and whole blood specimens. J Clin Virol. 2017;91:95-100. DOI: 10.1016/j.jcv.2017.03.019.
32. Malloch L, Kadivar K, Putz J, Levett PN, Tang J, Hatchette TF, et al. Comparative evaluation of the Bio-Rad Geenius HIV-1/2 Confirmatory Assay and the Bio-Rad Multispot HIV-1/2 Rapid Test as an alternative differentiation assay for CLSI M53 algorithm-I. J Clin Virol. 2013;58 Suppl 1:e85-91. DOI: 10.1016/j.jcv.2013.08.008.
33. Lange JM, Paul DA, Huisman HG, de Wolf F, van den Berg H, Coutinho RA, et al. Persistent HIV antigenaemia and decline of HIV core antibodies associated with transition to AIDS. Br Med J (Clin Res Ed). 1986;293(6560):1459-62. DOI: 10.1136/bmj.293.6560.1459.
34. Goudsmit J, Lange JM, Paul DA, Dawson GJ. Antigenemia and antibody titers to core and envelope antigens in AIDS, AIDS-related complex, and subclinical human immunodeficiency virus infection. J Infect Dis. 1987;155(3):558-60. DOI: 10.1093/infdis/155.3.558.
35. Fiscus SA, Pilcher CD, Miller WC, Powers KA, Hoffman IF, Price M, et al. Rapid, real-time detection of acute HIV infection in patients in Africa. J Infect Dis. 2007;195(3):416-24. DOI: 10.1086/510755.
36. Pandori MW, Hackett J, Jr., Louie B, Vallari A, Dowling T, Liska S, et al. Assessment of the ability of a fourth-generation immunoassay for human immunodeficiency virus (HIV) antibody and p24 antigen to detect both acute and recent HIV infections in a high-risk setting. J Clin Microbiol. 2009;47(8):2639-42. DOI: 10.1128/JCM.00119-09.
37. Stekler J, Maenza J, Stevens CE, Swenson PD, Coombs RW, Wood RW, et al. Screening for acute HIV infection: lessons learned. Clin Infect Dis. 2007;44(3):459-61. DOI: 10.1086/510747.
38. Rich JD, Merriman NA, Mylonakis E, Greenough TC, Flanigan TP, Mady BJ, et al. Misdiagnosis of HIV infection by HIV-1 plasma viral load testing: a case series. Ann Intern Med. 1999;130(1):37-9. DOI: 10.7326/0003-4819-130-1-199901050-00007.
39. Defo D, Kouotou EA, Nansseu JR. Failure to return to receive HIV-test results: the Cameroon experience. BMC Res Notes. 2017;10(1):309. DOI: 10.1186/s13104-017-2632-7.
40. Ngangue P, Bedard E, Zomahoun HT, Payne-Gagnon J, Fournier C, Afounde J, et al. Returning for HIV Test Results: A Systematic Review of Barriers and Facilitators. Int Sch Res Notices. 2016;2016:6304820. DOI: 10.1155/2016/6304820.
41. Keen P, Conway DP, Cunningham P, McNulty A, Couldwell DL, Davies SC, et al. Multi-centre field evaluation of the performance of the Trinity Biotech Uni-Gold HIV 1/2 rapid test as a first-line screening assay for gay and bisexual men compared with 4th generation laboratory immunoassays. J Clin Virol. 2017;86:46-51. DOI: 10.1016/j.jcv.2016.11.006.
42. Agutu CA, Ngetsa CJ, Price MA, Rinke de Wit TF, Omosa-Manyonyi G, Sanders EJ, et al. Systematic review of the performance and clinical utility of point of care HIV-1 RNA testing for diagnosis and care. PLoS One. 2019;14(6):e0218369. DOI: 10.1371/journal.pone.0218369.
43. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 2002;347(6):385-94. DOI: 10.1056/NEJMoa013552.
44. D'Costa J, Gooey M, Richards N, Sameer R, Lee E, Chibo D. Analysis of transmitted HIV drug resistance from 2005 to 2015 in Victoria, Australia: a comparison of the old and the new. Sex Health. 2017;14(6):558-65. DOI: 10.1071/SH16190.
45. Pillay D, Bhaskaran K, Jurriaans S, Prins M, Masquelier B, Dabis F, et al. The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy. AIDS. 2006;20(1):21-8. DOI: 10.1097/01.aids.0000196172.35056.b7.
46. Paredes R, Clotet B. Clinical management of HIV-1 resistance. Antiviral Res. 2010;85(1):245-65. DOI: 10.1016/j.antiviral.2009.09.015.
47. Lataillade M, Chiarella J, Yang R, Schnittman S, Wirtz V, Uy J, et al. Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naive subjects in the CASTLE study. PLoS One. 2010;5(6):e10952. DOI: 10.1371/journal.pone.0010952.
48. Pinto A, Carrera A, Salem H, Thapa K, Shaik A, Petoumenos K, et al. Evolution of HIV-1 Surveillance Drug Resistance Mutations Over 10 Years in New South Wales, Australia. AIDS Res Hum Retroviruses. 2021;37(12):897-902. DOI: 10.1089/AID.2016.0301.
49. Wawer MJ, Gray RH, Sewankambo NK, Serwadda D, Li X, Laeyendecker O, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis. 2005;191(9):1403-9. DOI: 10.1086/429411.
50. Hollingsworth TD, Anderson RM, Fraser C. HIV-1 transmission, by stage of infection. J Infect Dis. 2008;198(5):687-93. DOI: 10.1086/590501.
51. Pilcher CD, Fiscus SA, Nguyen TQ, Foust E, Wolf L, Williams D, et al. Detection of acute infections during HIV testing in North Carolina. N Engl J Med. 2005;352(18):1873-83. DOI: 10.1056/NEJMoa042291.
52. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Antiretroviral Therapy for the Prevention of HIV-1 Transmission. N Engl J Med. 2016;375(9):830-9. DOI: 10.1056/NEJMoa1600693.
53. Bavinton BR, Pinto AN, Phanuphak N, Grinsztejn B, Prestage GP, Zablotska-Manos IB, et al. Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study. Lancet HIV. 2018;5(8):e438-e47. DOI: 10.1016/S2352-3018(18)30132-2.
54. Pinto AN, Grey P, Shaik A, Cooper DA, Kelleher AD, Petoumenos K. Early Treatment of Primary HIV Infection Is Associated with Decreased Mortality. AIDS Res Hum Retroviruses. 2018;34(11):936-41. DOI: 10.1089/AID.2017.0284.
55. Kassutto S, Maghsoudi K, Johnston MN, Robbins GK, Burgett NC, Sax PE, et al. Longitudinal analysis of clinical markers following antiretroviral therapy initiated during acute or early HIV type 1 infection. Clin Infect Dis. 2006;42(7):1024-31. DOI: 10.1086/500410.
56. Investigators ST, Fidler S, Porter K, Ewings F, Frater J, Ramjee G, et al. Short-course antiretroviral therapy in primary HIV infection. N Engl J Med. 2013;368(3):207-17. DOI: 10.1056/NEJMoa1110039.
57. Group ISS, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, et al. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med. 2015;373(9):795-807. DOI: 10.1056/NEJMoa1506816.
58. Danel C, Moh R, Minga A, Anzian A, Ba-Gomis O, Kanga C, et al. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet. 2006;367(9527):1981-9. DOI: 10.1016/S0140-6736(06)68887-9.
59. Strategies for Management of Antiretroviral Therapy Study G, El-Sadr WM, Lundgren J, Neaton JD, Gordin F, Abrams D, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355(22):2283-96. DOI: 10.1056/NEJMoa062360.
60. Fida M, Rizza SA, Temesgen Z. Dolutegravir plus lamivudine dual therapy - a new option for initial antiretroviral therapy. Drugs Today (Barc). 2019;55(5):297-304. DOI: 10.1358/dot.2019.55.5.2962947.
61. Orkin C, Bernal Morell E, Tan DHS, Katner H, Stellbrink HJ, Belonosova E, et al. Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study. Lancet HIV. 2021;8(11):e668-e78. DOI: 10.1016/S2352-3018(21)00184-3.